JAKAFI Drug Patent Profile

Which patents cover Jakafi, and what generic alternatives are available?

Jakafi is a drug marketed by Incyte Corp and is included in two NDAs. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jakafi

Jakafi was eligible for patent challenges on November 16, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JAKAFI

International Patents:	236
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	81
Patent Applications:	1,634
Drug Prices:	Drug price information for JAKAFI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JAKAFI
What excipients (inactive ingredients) are in JAKAFI?	JAKAFI excipients list
DailyMed Link:	JAKAFI at DailyMed

See drug prices for JAKAFI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JAKAFI

NDA:

202192

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JAKAFI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pennsylvania	PHASE2
National Heart, Lung, and Blood Institute (NHLBI)	PHASE2
Incyte Corporation	PHASE2

See all JAKAFI clinical trials

Pharmacology for JAKAFI

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for JAKAFI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for JAKAFI

JAKAFI is protected by eight US patents and six FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-005	May 1, 2026		RX	Yes	Yes
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-001	May 1, 2026		RX	Yes	No			Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No					Y

International Patents for JAKAFI

When does loss-of-exclusivity occur for JAKAFI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Nicaragua

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAKAFI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008266183
Brazil	PI0814254
Canada	2689663
China	101932582

Supplementary Protection Certificates for JAKAFI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	C300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	PA2013002	Lithuania
1966202	CA 2013 00005	Denmark
1966202	C20130003 00072	Estonia		PRODUCT NAME: RUKSOLITINIIB;REG NO/DATE: K(2012)6018 LOPLIK 23.08.2012

Jakafi (ruxolitinib) market dynamics and financial trajectory: exclusivity, competitive pressure, and revenue outlook

Last updated: July 20, 2026

Jakafi (ruxolitinib) is a first-in-class JAK inhibitor tied to Jakafi’s hematology franchise (myelofibrosis and polycythemia vera) and to later label expansions (acute graft-versus-host disease and chronic GVHD). The drug’s market trajectory in the US and major ex-US markets is shaped by (1) patent and exclusivity timing for ruxolitinib formulations and uses, (2) competitive encroachment from other JAK inhibitors and JAK switching/combination strategies, and (3) payer and site-of-care pressures driven by high-cost specialty spend.

High-level snapshot (US commercial logic)

• Core revenue drivers: myelofibrosis (MF), polycythemia vera (PV), steroid-refractory acute GVHD (aGVHD) and chronic GVHD after prior therapy.
• Key market risks: loss of ruxolitinib “brand exclusivity” components, generic erosion dynamics, and channel/payer formulary shifts as competitors improve outcomes or access.
• Key upside levers: label durability across subpopulations, ongoing evidence generation, and stronger positioning in GVHD lines where alternative options may be less differentiated.

Which diseases does Jakafi treat and how do those indications shape sales volatility?

Jakafi’s financial trajectory is primarily a function of indication mix, with MF and PV historically carrying the bulk of US demand, and GVHD contributing incremental growth and durability as treatment algorithms expand.

Myelofibrosis (MF): the core of the franchise

• MF is the largest commercial indication in most ruxolitinib commercial models because of high unmet need and persistent chronic treatment duration.
• MF demand sensitivity typically tracks:
  • severity distribution across risk strata,
  • treatment line progression (front-line vs later-line penetration),
  • discontinuation rates and dose modifications due to cytopenias.

Polycythemia vera (PV): smaller but strategically important

• PV demand depends on response depth and durability, and on whether physicians prefer ruxolitinib over alternative cytoreductive strategies.
• PV is payer-sensitive due to long-term chronic dosing and monitoring requirements.

Acute graft-versus-host disease (aGVHD) and chronic GVHD: mix shift and duration effects

• GVHD dosing is often time-limited early and longer for chronic disease, creating a different revenue curve than MF/PV.
• Commercial performance can be influenced by center-of-excellence adoption patterns and payer prior authorization practices.

What patents protect Jakafi and how do they affect market dynamics?

Jakafi’s long-run revenue trajectory depends on how many enforceable patents remain around:

• the active ingredient (ruxolitinib),
• key compositions (including tablet and other dosage/formulation variants),
• method-of-use claims by indication (MF, PV, GVHD),
• and any additional patent families covering dosing regimens or patient subgroups.

How patent coverage translates into generic entry risk

For small-molecule brands like Jakafi, competitive pressure typically accelerates when:

1. composition-of-matter coverage weakens or expires,
2. method-of-use coverage is narrowed or invalidated,
3. Orange Book-listed patents tied to key indications are no longer enforceable.

When enforceable patents fall away, the market moves from “brand-protected pricing” to “discounting and substitution,” even when generics may be launched later than some theoretic expiry dates.

When does Jakafi lose exclusivity in the US and EU?

Jakafi’s exclusivity timing is not one single date; the commercial calendar tracks:

• regulatory exclusivity (where applicable),
• patent-by-patent expiration,
• and any pediatric exclusivity extensions (if triggered within the applicable regulatory framework).

Revenue impact of staggered expiries

• MF and PV tend to be hardest hit when generic substitution becomes practical in those indications.
• GVHD can remain better protected longer if method-of-use patents tied to specific GVHD regimens remain enforceable or if clinical differentiation supports brand retention even after generic availability.

What is the Orange Book status of Jakafi and which patents would drive Paragraph IV challenges?

For US market access timing, the Orange Book patent list is the operational map. The trigger for “earliest possible generic entry” often depends on:

• which Orange Book-listed patents cover each approved indication,
• how many patents are carved out by the generic applicant,
• and whether the case settles with a design-around or a delayed launch.

How to think about Paragraph IV economics for Jakafi

Generic applicants typically attack:

• composition-of-matter or broadly applicable formulation patents,
• method-of-use patents that cover high-volume indications,
• or patents with the widest claim scope for the approved labeling.

If the litigation landscape favors the innovator, generic launches can be delayed by years, compressing the generics’ expected net present value and often shrinking the number of challengers.

How strong is the patent estate for Jakafi versus ruxolitinib competitors?

The practical question is not whether patents exist, but whether they are:

• enforceable in relevant jurisdictions,
• broad enough to cover non-substitutable patient outcomes,
• and anchored to Orange Book listings that block generic labeling.

Competitive patent-positioning: brand vs class

Jakafi faces class competition from other JAK inhibitors and, in some scenarios, from non-JAK options depending on guideline updates and payer preference. Patent strength matters because it determines how long the brand can keep pricing and access leverage before generic substitution changes negotiation dynamics.

Which companies are challenging Jakafi and what litigation affects generic entry?

Jakafi’s generic and biosimilar landscape is dominated by generic small-molecule challenges rather than biologics. For a small-molecule JAK inhibitor, the largest litigation impact comes from:

• Paragraph IV cases tied to Orange Book patents,
• and settlements that define “launch dates” and labeling carve-outs.

What to watch in litigation for revenue exposure

Key litigation signals that affect revenue planning:

• settlements that impose delayed entry or limit generic labels,
• claim construction outcomes that narrow enforceable scope,
• and any injunction outcomes affecting specific indications.

What formulations are protected by Jakafi patents and how does formulation drive competition?

For ruxolitinib, formulation issues can include:

• tablet composition and manufacturing processes,
• specific dosage strengths and release characteristics (if claimed),
• and any incremental inventions that extend commercial life.

Dose-strength coverage and substitution

In practice, even when generics enter for some strengths, commercial impact can be uneven if:

• specific doses used in titration schedules remain brand-preferred,
• payers require step edits or prior authorizations,
• or physicians are slow to switch stable patients.

What commercial dynamics determine Jakafi pricing power year to year?

Jakafi’s pricing trajectory is shaped by specialty drug contracting and channel mix rather than list price alone.

Payer tactics that hit JAK inhibitor revenue

• formulary placement shifts and step-therapy protocols,
• preferred specialty pharmacy routing,
• higher cost-sharing for non-preferred plans,
• and MAC pressure where coverage windows allow.

Center of care and prescribing inertia

In hematology and transplant settings, switching patterns depend on:

• physician familiarity,
• clinical protocols,
• and patient stability on therapy.

This is why revenue decline after generic availability is often slower than generic price discounting would predict, especially in MF.

How does Jakafi compare with other JAK inhibitors on efficacy, access, and switching?

Jakafi competes against other JAK inhibitors and, in some indications, against non-JAK therapies depending on guideline positioning. The revenue consequence of competition is usually a mix of:

• clinical differentiation that retains share,
• and contracting that reduces payer net price.

Switching risk: where it tends to concentrate

• PV and MF are sensitive to perceived efficacy and tolerability.
• GVHD is sensitive to transplant-center pathways and institutional adherence.

Even if rivals are clinically competitive, brand retention can persist if payer rules support Jakafi coverage and if formularies allow continuation therapy.

What generic entry risks exist for Jakafi and what launch scenarios would matter financially?

Generic entry risks are best modeled as three scenarios:

1. early entry with broad label coverage,
2. delayed entry due to litigation or settlements,
3. partial label carve-outs that limit use in the highest-volume indications.

Scenario math (what drives revenue compression)

Revenue compression after generic entry typically comes from:

• immediate unit share loss in covered indications,
• steep net price declines due to payer renegotiation,
• and downstream shifts in patient initiation volumes.

The effect can be moderated by:

• continued brand exclusivity for certain indications,
• higher generic utilization friction,
• and brand-supported patient access programs.

How does biosimilar risk apply to Jakafi?

Jakafi is a small-molecule drug, so biosimilar risk is not the relevant threat. Commercial pressure comes from:

• generic small-molecule competition,
• competitor JAK inhibitors,
• and payer preference shifts within the same mechanism class.

What FDA and reimbursement milestones influence Jakafi financial trajectory?

FDA-related milestones that typically move commercial outcomes include:

• label expansions that add patient populations,
• safety updates that affect dosing or persistence,
• and any restriction changes that affect coverage.

Real-world reimbursement

Even with stable label, reimbursement evolves through:

• payer medical policy updates,
• specialty pharmacy distribution rules,
• and revisions to prior authorization criteria.

Market outlook: what should investors assume about Jakafi revenue over the next 3–5 years?

Jakafi’s outlook hinges on whether generic pressures arrive while label expansion growth offsets them. The most revenue-relevant question is whether:

• the remaining patent stack can maintain meaningful barriers to generic entry,
• competitors win share via contracting leverage and clinical adoption,
• and payer net pricing remains resilient.

In most specialty drug frameworks, once generic availability becomes practical in MF and PV, revenue decline accelerates unless brand share is protected by differentiated access, clinical positioning, or litigation-driven delay.

Key Takeaways

• Jakafi’s financial trajectory is indication-mix driven: MF and PV drive baseline demand; GVHD adds durable incremental revenue where access policies support continuation.
• Patent and Orange Book status determine generic entry timing and whether challengers can launch with broad labeling coverage.
• Commercial dynamics are payer-contract driven: formulary placement, step edits, prior authorization rules, and net price erosion typically drive year-to-year revenue changes.
• Competitive pressure is mechanism-class based: other JAK inhibitors can shift share even before generics arrive if payer contracting favors alternatives.
• The highest financial risk occurs when enforceable Orange Book patents tied to MF/PV fall away and generic substitution becomes operational.

FAQs

1. How does Jakafi net price change after generic entry in the US?
2. Which Jakafi indications are most vulnerable to formulary restrictions by payers?
3. How do settlements in Paragraph IV litigations typically impact generic launch timelines for Jakafi?
4. What dosing and monitoring factors most influence persistence and thus revenue in MF treated with Jakafi?
5. How does competitor contracting within the JAK inhibitor class affect Jakafi’s prescribing share?

References

1. APA format reference list not provided because no specific source citations were included in the prompt content.

DrugChatter Q&A for JAKAFI

Incyte corporation jakafi 3q25 u's sales forecast?
Jakafi medication canada price generic timeline?
Jakafi ongoing clinical trials?
When does jakafi go generic?
When will jakafi patent expire?